United Kingdom (UK)
Recombinant monoclonal antibody to Il-8. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 5.12.14.
UniProt Accession Number of Target Protein: P10145
Alternative Name(s) of Target: Interleukin-8; Il8; II-8; Il 8; C-X-C motif chemokine 8; Chemokine (C-X-C motif) ligand 8; Emoctakin; Granulocyte chemotactic protein 1; GCP-1; Monocyte-derived neutrophil chemotactic factor; MDNCF; Monocyte-derived neutrophil-activating peptide; MONAP; Neutrophil-activating protein 1; NAP-1; Protein 3-10C; T-cell chemotactic factor
Immunogen: This antibody was raised by immunising Balc/c mice against conjugated Il-8.
Specificity: This antibody recognises Interleukin-8 (Il-8) which is a neutrophil chemotactic peptide. It is secreted by many different cells which had been activated by inflammatory stimuli. It is specific to Il-8 and does not bind to other chemokins, such as C5a, platelet factor 4 or β-TG.
Application Notes: This antibody is an Il-8 antagonist and prevents binding to neutrophils, which might be used in research aiming at treating asthma (before or after its onset) (US5874080A). Furthermore, this antibody inhibits both Il-8-dependent neutrophil chemotaxis and neutrophil elastase release (US5874080A).
Antibody first published in:
Hebert et al. Anti-IL-8 monoclonal antibodies for treatment of asthma Hebert, C.A., Kabakoff, R.C. and Moore, M.W., Genentech Inc, 1999. Anti-IL-8 monoclonal antibodies for treatment of asthma. U.S. Patent 5,874,080. PMID:
Note on publication:
This patent describes the generation and characterisation of the 5.12.14 antibody.